WPI 900 (Glipizide extended release 2.5 mg)
Pill imprint WPI 900 has been identified as Glipizide extended release 2.5 mg.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 2.5 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for WPI 900 (Glipizide extended release 2.5 mg)
Glipizide extended release
- Imprint:
-
WPI 900
- Strength:
- 2.5 mg
- Color:
- Yellow
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Sulfonylureas
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Watson Pharmaceuticals
- National Drug Code (NDC):
- 00591-0900
| NDC Code | Manufacturer / Repackager |
|---|---|
| 00228-2898 | Actavis |
| 68084-0295 | Amerisource Health Services |
Note: Inactive ingredients may vary.
More resources
Glipizide extended release is associated with the treatment of:
Search Again
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...
